Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer.
- Author:
Fei CUI
1
;
Jin-zhang CHEN
;
Cheng WAN
;
Bin CHEN
;
Rong-cheng LUO
;
Hang ZHENG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antibodies, Monoclonal; therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bevacizumab; Camptothecin; administration & dosage; analogs & derivatives; Colorectal Neoplasms; drug therapy; pathology; Female; Fluorouracil; administration & dosage; Humans; Leucovorin; administration & dosage; Male; Middle Aged; Neoplasm Metastasis; drug therapy; Neoplasm Staging; Survival Rate
- From: Chinese Journal of Gastrointestinal Surgery 2009;12(4):374-377
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment.
METHODSSixty-two patients were randomly divided into two groups, group A of 30 patients received bevacizumab plus irinotecan, fluorouracil and leucovorin, group B of 32 patients received irinotecan, fluorouracil and leucovorin. The response rate,change of tumor markers,one year survival rate and safety were observed.
RESULTSTumor response rate was 30% in group A, 21.8% in group B respectively. Disease control rate(CR+PR+SD) was 80% in group A, 50% in group B. The obvious change of concentration of tumor markers was observed between pre-treatment and post-treatment, which was significantly different in group A(P<0.05). One year survival rate, median of time to progression and median duration of survival between group A and group B were 26.7% vs 18.8%, 5.9 months vs 3.9 months, 10.9 months vs 8.9 months(P<0.05). The adverse effect in group A was the same as group B. Bevacizumab was associated with hypertension and bradycardia.
CONCLUSIONSThe chemotherapy of bevacizumab combined with irinotecan, fluorouracil and leucovorin results in better efficacy in patients with progressive metastatic colorectal cancer.
